These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33658640)

  • 1. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
    Gampala S; Shah F; Zhang C; Rhodes SD; Babb O; Grimard M; Wireman RS; Rad E; Calver B; Bai RY; Staedtke V; Hulsey EL; Saadatzadeh MR; Pollok KE; Tong Y; Smith AE; Clapp DW; Tee AR; Kelley MR; Fishel ML
    Br J Cancer; 2021 Apr; 124(9):1566-1580. PubMed ID: 33658640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
    Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
    Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
    Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
    J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.
    Cardoso AA; Jiang Y; Luo M; Reed AM; Shahda S; He Y; Maitra A; Kelley MR; Fishel ML
    PLoS One; 2012; 7(10):e47462. PubMed ID: 23094050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
    Caston RA; Shah F; Starcher CL; Wireman R; Babb O; Grimard M; McGeown J; Armstrong L; Tong Y; Pili R; Rupert J; Zimmers TA; Elmi AN; Pollok KE; Motea EA; Kelley MR; Fishel ML
    J Cell Mol Med; 2021 Jan; 25(2):784-800. PubMed ID: 33274592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
    Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer.
    Fishel ML; Xia H; McGeown J; McIlwain DW; Elbanna M; Craft AA; Kaimakliotis HZ; Sandusky GE; Zhang C; Pili R; Kelley MR; Jerde TJ
    Mol Cancer Ther; 2019 Nov; 18(11):1947-1960. PubMed ID: 31413178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types.
    Gampala S; Moon HR; Wireman R; Peil J; Kiran S; Mitchell DK; Brewster K; Mang H; Masters A; Bach C; Smith-Kinnamen W; Doud EH; Rai R; Mosley AL; Quinney SK; Clapp DW; Hamdouchi C; Wikel J; Zhang C; Han B; Georgiadis MM; Kelley MR; Fishel ML
    Pharmacol Res; 2024 Mar; 201():107092. PubMed ID: 38311014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?
    Gaspard M; Lamant L; Tournier E; Valentin T; Rochaix P; Terrier P; Ranchere-Vince D; Coindre JM; Filleron T; Le Guellec S
    Histopathology; 2018 Dec; 73(6):969-982. PubMed ID: 30137667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
    Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.
    Fishel ML; Jiang Y; Rajeshkumar NV; Scandura G; Sinn AL; He Y; Shen C; Jones DR; Pollok KE; Ivan M; Maitra A; Kelley MR
    Mol Cancer Ther; 2011 Sep; 10(9):1698-708. PubMed ID: 21700832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
    Chang LS; Oblinger JL; Burns SS; Huang J; Anderson LW; Hollingshead MG; Shen R; Pan L; Agarwal G; Ren Y; Roberts RD; O'Keefe BR; Kinghorn AD; Collins JM
    Mol Cancer Ther; 2020 Mar; 19(3):731-741. PubMed ID: 31848295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
    Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
    Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
    Logsdon DP; Grimard M; Luo M; Shahda S; Jiang Y; Tong Y; Yu Z; Zyromski N; Schipani E; Carta F; Supuran CT; Korc M; Ivan M; Kelley MR; Fishel ML
    Mol Cancer Ther; 2016 Nov; 15(11):2722-2732. PubMed ID: 27535970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.
    Ding J; Fishel ML; Reed AM; McAdams E; Czader MB; Cardoso AA; Kelley MR
    Mol Cancer Ther; 2017 Jul; 16(7):1401-1411. PubMed ID: 28446640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target.
    Gampala S; Shah F; Lu X; Moon HR; Babb O; Umesh Ganesh N; Sandusky G; Hulsey E; Armstrong L; Mosely AL; Han B; Ivan M; Yeh JJ; Kelley MR; Zhang C; Fishel ML
    J Exp Clin Cancer Res; 2021 Aug; 40(1):251. PubMed ID: 34376225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.